Background <p>Prostate cancer (PCa) is widely recognized as an immunologically "cold" tumor, characterized by a paucity of effector T cells and a limited response to immune checkpoint blockade therapy. Although the chemokine receptor CXCR6 has been identified as a marker of highly cytotoxic CD8<sup>+</sup> T cells in other malignancies, its identity, regulatory mechanisms, and clinical significance in PCa remain poorly…
Dual regulation of CXCR6+CD8+ T cells modulates cytotoxic and exhaustion-associated programs during prostate cancer progression
Journal for ImmunoTherapy of Cancer | | Xingming, Z., Wang, J., Abudurexiti, M., Du, L., Zhang, W., Ni, X., Xu, M., Zhang, X., Zhang, M., Yao, Z., Bian, X., Jin, S., Wang, W.
Topics: prostate-cancer, blood-cancer, immunotherapy, chemotherapy, research
Read the full article at Journal for ImmunoTherapy of Cancer